1. Home
  2. LRE vs TIL Comparison

LRE vs TIL Comparison

Compare LRE & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lead Real Estate Co. Ltd

LRE

Lead Real Estate Co. Ltd

HOLD

Current Price

$1.32

Market Cap

20.5M

Sector

N/A

ML Signal

HOLD

Logo Instil Bio Inc.

TIL

Instil Bio Inc.

HOLD

Current Price

$11.21

Market Cap

74.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LRE
TIL
Founded
2001
2018
Country
Japan
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.5M
74.7M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
LRE
TIL
Price
$1.32
$11.21
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$100.67
AVG Volume (30 Days)
7.3K
58.7K
Earning Date
01-01-0001
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
32.27
N/A
EPS
0.43
N/A
Revenue
$130,601,512.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.11
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$10.69
52 Week High
$2.97
$42.79

Technical Indicators

Market Signals
Indicator
LRE
TIL
Relative Strength Index (RSI) 45.12 42.30
Support Level $1.29 $10.96
Resistance Level $1.45 $11.63
Average True Range (ATR) 0.07 0.55
MACD 0.01 0.27
Stochastic Oscillator 30.73 58.80

Price Performance

Historical Comparison
LRE
TIL

About LRE Lead Real Estate Co. Ltd

Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Share on Social Networks: